REFERENCES
- Bodey G P, Buckley M, Sathe Y S, et al, Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64: 328–340. [PUBMED], [INFOTRIEVE]
- Chanock S J, Piazzo P A. Fever in the neutropenic host. Infect Dis Clin North Am. 1996; 10: 777–796. [PUBMED], [INFOTRIEVE]
- Quadri T L, Brown A E. Infectious complications in the critically ill patient with cancer. Semin Oncol. 2000; 27: 335–346. [PUBMED], [INFOTRIEVE]
- Klastersky J. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness. Curr Opin Oncol. 1998; 10: 284–290. [PUBMED], [INFOTRIEVE]
- Freifeld A G, Wlash T J, Pizzo P A. Infectious complications in the pediatric cancer patient. Pizzo P A, Poplack D G. Principles and Practise of Pediatric Oncology. Philadelphia, Lippincott– Raven. 1997; 1069–1114
- Hughes W T, Armstrong D, Bodey G P, et al, 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730–751. [PUBMED], [INFOTRIEVE]
- Pizzo P A. Evaluation of fever in the patients with cancer. Eur J Cancer. 1989; 25: 9–16
- Hann I, Viscoli C, Paesmans M, et al, A comprasion of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Hematol. 1997; 99: 580–588
- Viscoli C, Castagnola C. Planned progressive antimicrobial therapy in neutropenic patients. Br J Hematol. 1998; 102: 879–888
- Hughes W T, Armstrong D, Bodey G P, et al, Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990; 161: 381–396. [PUBMED], [INFOTRIEVE]
- Gaya H. Empirical therapy of infections in neutropenic patients. Br J Hematol. 1996; 101: 5–9
- Giamarellou H, Bassaris H P, Petrikkos G, et al, Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empric therapy for granulocytopenic patients with fever.. Antimicrob Agents Chemother. 2000; 44: 3264–3271. [PUBMED], [INFOTRIEVE]
- Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative. Clin Infect Dis. 1999; 29: 508–514. [PUBMED], [INFOTRIEVE]
- Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis. 1999; 29: 503–507. [PUBMED], [INFOTRIEVE]
- Rubin M, Hathorn J W, Marshall D, et al, Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988; 108: 30–35. [PUBMED], [INFOTRIEVE]
- Mermel L A, Farr B M, Sherertz R J, et al, Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001; 32: 1249–1272. [PUBMED], [INFOTRIEVE]
- Ağaoglu L, Devecioğlu O, Anak S, et al, Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother. 2001; 13: 281–287
- Mullen C A, Petropoulos D, Roberts W M, et al, Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol. 1999; 21: 212–218. [PUBMED], [INFOTRIEVE]
- Rosenman M, Madsen K, Hui S, et al, Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges. J Pediatr Hematol Oncol. 2002; 24: 263–268. [PUBMED], [INFOTRIEVE]
- Leese B, Collin R, Clark D J. The cost of treating febrile neutropenia in patient with malignant blood disorders. Pharmacoeconomics. 1994; 6: 233–239. [PUBMED], [INFOTRIEVE]
- Dranitsaris G, Tran T M, McGeer A, et al, Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics. 1995; 7: 49–62. [PUBMED], [INFOTRIEVE]
- Rahiala J, Perkkio M, Riikonen P. Prospective and randomized comprasion of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol. 1999; 32: 326–330. [PUBMED], [INFOTRIEVE]
- Ayan I, Kebudi R, Dogan S, et al, Granulocyte colony-stimulating factor in neutropenic, pediatric solid tumor patients following chemotherapy. Pediatr Hematol Oncol. 1996; 13: 417–424. [PUBMED], [INFOTRIEVE]
- Pinkala UMS, Lanning M, Perkkiö M, et al, Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblactic leukemia in children. Med Pediatr Oncol. 2000; 34: 319–327
- American Society of Clinical Oncology, Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines.. J Clin Oncol. 1996; 14: 1957–1960